Study S001302

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Tirzepatide Once Weekly Compared to Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

ClinicalTrials.gov record

Registration

Registration: NCT06962280
Acronym: SURPASS-T1D-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 465
Start: 2025-05-12
Primary completion: 2026-11
Lead sponsor: Eli Lilly and Company
Conditions: Type 1 Diabetes; Obesity; Overweight
Interventions: DRUG:Tirzepatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPJD; CTIS:2024-519685-51-00

Registered primary outcomes

Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 40]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.